Travere Therapeutics Reports First Quarter 2022 Financial Results

SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) reported its first quarter 2022 financial results and provided a corporate update.

Read the full press release >

Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy